Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/10/2018 |
| Start Date: | November 5, 2015 |
| End Date: | November 1, 2026 |
| Contact: | Nancy D. Perrier, MD |
| Phone: | 713-792-6940 |
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients
Objectives:
The aim of the present study is to assess the significance of metabolomics and genetics in
diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients.
Aim 1: To evaluate the relationship of serum global metabolic profiles with subsequent
development of aggressive PNET and evaluate patients survival in a nested case-control study
of MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have
developed non-aggressive PNETs (controls).
Aim 2: Validate the top serum metabolites identified from Aim 1 in MEN1 patients who have
developed aggressive PNETs and MEN1 patients who have developed non-aggressive PNETs, using a
targeted metabolomics approach.
Aim 3: Prospectively identify the potential miRNA biomarkers of serum with miRNA sequencing
in MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have
developed non-aggressive PNETs (controls).
Aim 4: Validate the potential miRNA biomarkers identified from Aim 1 in MEN1 patients who
have developed aggressive PNETs and in MEN1 patients who have developed non-aggressive PNETs,
using a targeted qRT-PCR approach (in serums), as well as to see the relationship of
potential miRNA biomarkers with patients survival.
The aim of the present study is to assess the significance of metabolomics and genetics in
diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients.
Aim 1: To evaluate the relationship of serum global metabolic profiles with subsequent
development of aggressive PNET and evaluate patients survival in a nested case-control study
of MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have
developed non-aggressive PNETs (controls).
Aim 2: Validate the top serum metabolites identified from Aim 1 in MEN1 patients who have
developed aggressive PNETs and MEN1 patients who have developed non-aggressive PNETs, using a
targeted metabolomics approach.
Aim 3: Prospectively identify the potential miRNA biomarkers of serum with miRNA sequencing
in MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have
developed non-aggressive PNETs (controls).
Aim 4: Validate the potential miRNA biomarkers identified from Aim 1 in MEN1 patients who
have developed aggressive PNETs and in MEN1 patients who have developed non-aggressive PNETs,
using a targeted qRT-PCR approach (in serums), as well as to see the relationship of
potential miRNA biomarkers with patients survival.
Inclusion Criteria:
1. The study will include all patients with a confirmed MEN1 diagnosis (clinical, genetic
or familial criteria).
2. No prior history of PNET.
Exclusion Criteria:
We found this trial at
1
site
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
